Celldex Therapeutics, Inc. (CLDX)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Celldex Therapeutics’ earnings for the third fiscal quarter of 2026, reported November 5, 2026, topped consensus on EPS in preliminary results, with EPS of -$0.96 topping the -$1.02 estimate by $0.06. The quarter still posted a GAAP net loss, with net income of roughly -$75.6 million, widening about 13% year over year from roughly -$67.0 million, as the antibody-based biotechnology company continues to advance pipeline programs including CDX-0159, CDX-1140, and CDX-527. Cash burn remained evident in the period, with negative operating cash flow of about -$65.0 million.
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. develops antibody-based treatments as a biotechnology company in the healthcare sector and trades on the NASDAQ under CLDX. Founded in 1983, Celldex is a small-cap drug developer focused on monoclonal and bispecific antibodies aimed at inflammatory diseases and cancers.
Today's Snapshot
CLDX closed 1.8% lower at 27.55, in line with a weaker sector.
Trading Volume
Below 10d avg (849.0K)
679.5K
vs S&P 500 Today
Underperforming Market
-1.49%
Updated: November 18, 2026 at 21:27 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$28.86 - $32.67Sell
- RSI (14)38.45Neutral
- Stochastic %K (14, 3, 3)11.66Buy
- MACD Level (12, 26)-0.76Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.